Iovance Biotherapeutics Financial Statements (IOVA)
|
|
|
|
Report date
|
|
|
25.02.2020 |
25.02.2021 |
24.02.2022 |
28.02.2023 |
28.02.2024 |
|
07.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
0.000 |
0.000 |
0.000 |
0.000 |
1.19 |
|
90.9 |
|
Operating Income, bln rub |
|
|
-206.9 |
-261.9 |
-342.7 |
-398.9 |
-460.6 |
|
-430.0 |
|
EBITDA, bln rub |
? |
|
-189.4 |
-250.9 |
-328.3 |
-374.8 |
-427.4 |
|
-396.4 |
|
Net profit, bln rub |
? |
|
-187.1 |
-257.2 |
-327.8 |
-389.9 |
-444.0 |
|
-410.0 |
|
|
OCF, bln rub |
? |
|
-158.9 |
-205.1 |
-227.9 |
-292.8 |
-361.8 |
|
-363.7 |
|
CAPEX, bln rub |
? |
|
6.92 |
46.8 |
37.6 |
20.4 |
22.3 |
|
10.4 |
|
FCF, bln rub |
? |
|
-165.8 |
-251.9 |
-265.5 |
-313.2 |
-384.1 |
|
-374.1 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
206.9 |
261.9 |
342.7 |
398.9 |
451.0 |
|
417.6 |
|
Cost of production, bln rub |
|
|
8.12 |
8.71 |
14.0 |
21.1 |
10.8 |
|
103.2 |
|
R&D, bln rub |
|
|
166.0 |
201.7 |
259.0 |
294.8 |
344.1 |
|
297.6 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
2.99 |
0.000 |
|
3.49 |
|
|
Assets, bln rub |
|
|
344.7 |
768.5 |
777.3 |
664.0 |
780.4 |
|
991.1 |
|
Net Assets, bln rub |
? |
|
299.0 |
656.5 |
621.7 |
499.6 |
584.6 |
|
773.5 |
|
Debt, bln rub |
|
|
11.5 |
51.7 |
71.5 |
84.4 |
75.9 |
|
78.9 |
|
Cash, bln rub |
|
|
307.1 |
629.4 |
596.0 |
471.8 |
279.9 |
|
397.5 |
|
Net debt, bln rub |
|
|
-295.6 |
-577.8 |
-524.5 |
-387.4 |
-204.0 |
|
-318.5 |
|
|
Ordinary share price, rub |
|
|
27.7 |
46.4 |
19.1 |
6.39 |
8.13 |
|
3.88 |
|
Number of ordinary shares, mln |
|
|
124.3 |
138.3 |
153.4 |
159.3 |
235.1 |
|
303.3 |
|
|
Market cap, bln rub |
|
|
3 442 |
6 417 |
2 929 |
1 018 |
1 912 |
|
1 177 |
|
EV, bln rub |
? |
|
3 146 |
5 839 |
2 404 |
630 |
1 708 |
|
858 |
|
Book value, bln rub |
|
|
299 |
656 |
622 |
500 |
355 |
|
467 |
|
|
EPS, rub |
? |
|
-1.50 |
-1.86 |
-2.14 |
-2.45 |
-1.89 |
|
-1.35 |
|
FCF/share, rub |
|
|
-1.33 |
-1.82 |
-1.73 |
-1.97 |
-1.63 |
|
-1.23 |
|
BV/share, rub |
|
|
2.40 |
4.75 |
4.05 |
3.14 |
1.51 |
|
1.54 |
|
|
EBITDA margin, % |
? |
|
|
|
|
|
-35 949% |
|
-436.2% |
|
Net margin, % |
? |
|
|
|
|
|
-37 345% |
|
-451.3% |
|
FCF yield, % |
? |
|
-4.82% |
-3.93% |
-9.07% |
-30.8% |
-20.1% |
|
-31.8% |
|
ROE, % |
? |
|
-62.6% |
-39.2% |
-52.7% |
-78.0% |
-76.0% |
|
-53.0% |
|
ROA, % |
? |
|
-54.3% |
-33.5% |
-42.2% |
-58.7% |
-56.9% |
|
-41.4% |
|
|
P/E |
? |
|
-18.4 |
-24.9 |
-8.93 |
-2.61 |
-4.31 |
|
-2.87 |
|
P/FCF |
|
|
-20.8 |
-25.5 |
-11.0 |
-3.25 |
-4.98 |
|
-3.15 |
|
P/S |
? |
|
|
|
|
|
1 608 |
|
13.0 |
|
P/BV |
? |
|
11.5 |
9.77 |
4.71 |
2.04 |
5.38 |
|
2.52 |
|
EV/EBITDA |
? |
|
-16.6 |
-23.3 |
-7.32 |
-1.68 |
-4.00 |
|
-2.17 |
|
Debt/EBITDA |
|
|
1.56 |
2.30 |
1.60 |
1.03 |
0.48 |
|
0.80 |
|
|
R&D/CAPEX, % |
|
|
2 400% |
431.1% |
689.4% |
1 443% |
1 544% |
|
2 853% |
|
|
CAPEX/Revenue, % |
|
|
|
|
|
|
1 875% |
|
11.5% |
|
| Iovance Biotherapeutics shareholders |
